top of page

OTX-TKI 12-month data and the program’s future with Ocular Therapeutix’s CEO

Ocular Therapeutix CEO Antony Mattessich describes the 12-month data his company has reported for its extended release TKI for wet AMD.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page